Fig. 2.

HRs (solid line) and 95% confidence limits (dotted lines) for malignant neoplasms (a–c) and mortality (d–f) for aspart (a, d), lispro (b, e) and glargine (c, f) based on the final models shown in ESM 2 and ESM 3. Because of the interaction with dose, the HRs change with varying dose levels. For mortality, the final model includes an additional interaction of glargine with age. Therefore, the HR curve shown for glargine refers to a fixed age of 70 years. The curves are plotted between the 5% and the 95% quantiles of the observed data for each insulin analogue